Axsome Therapeutics (AXSM) Highlights New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid & Significant Improvements in Patient-Reported Outcomes in MDD - StreetInsider.com
Submitted by Anonymous (not verified) on Mon, 09/14/2020 - 10:03
